nVerses Capital LLC Acquires Shares of 4,000 AxoGen, Inc. (NASDAQ:AXGN)

nVerses Capital LLC bought a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,000 shares of the medical equipment provider’s stock, valued at approximately $56,000.

Other institutional investors have also modified their holdings of the company. Koss Olinger Consulting LLC bought a new position in AxoGen in the second quarter worth approximately $75,000. Lazard Asset Management LLC grew its position in shares of AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock worth $93,000 after buying an additional 2,671 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of AxoGen during the second quarter valued at $125,000. BNP Paribas Financial Markets raised its holdings in shares of AxoGen by 8.6% in the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after acquiring an additional 1,651 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in AxoGen in the third quarter worth about $227,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Trading Down 0.1 %

NASDAQ:AXGN opened at $13.15 on Tuesday. The stock has a market capitalization of $574.72 million, a price-to-earnings ratio of -26.30 and a beta of 1.13. AxoGen, Inc. has a 52 week low of $3.45 and a 52 week high of $15.23. The company has a quick ratio of 2.32, a current ratio of 3.51 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $13.35 and a 200 day moving average of $9.50.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. The firm had revenue of $47.91 million during the quarter, compared to analyst estimates of $43.27 million. As a group, sell-side analysts anticipate that AxoGen, Inc. will post -0.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have commented on AXGN. JMP Securities raised their target price on shares of AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research report on Friday, August 9th. Raymond James began coverage on shares of AxoGen in a research note on Monday, July 1st. They issued an “outperform” rating and a $13.00 price objective for the company. Finally, StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $15.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.